relationships relevant to the contents of this paper to disclose. An additional issue in considering the clinical importance of the current data relates to the mathematics of heart failure prevention as a concept. PDD is present in a large percentage of the adult population (25% to 33%) (11), or >60 million Americans.
Although PDD is a clear precursor for HFpEF, the rate of transition from PDD to symptomatic heart failure is relatively low (2% to 3% per year). Thus, even if SQ BNP as studied in the current trial was highly safe and efficacious in preventing the development of heart failure, the prospect of treating millions of asymptomatic persons with twice daily injections to prevent the development of symptomatic heart failure is both logistically and economically daunting. E-mail: Michael.felker@duke.edu.
